Ovarian cancer is a type of cancer that begins in the ovaries.
It is the 7th most common cancer in women (excluding skin cancer) and the leading cause of death from gynecologic cancer in developed countries.
The 3 histologic types of ovarian cancer are epithelial (primarily seen in women >50 years of age), germ cell (most commonly seen in women <20 years of age) and sex cord stromal (rare and produces steroid hormones).
The median age at the time of diagnosis is 63 years old and >70% present with advanced disease.
The CA125* test could be useful at detecting ovarian cancer and various other cancers in the primary care setting, particularly for women aged >50 years, according to a study presented at the recent NCRI** Cancer Conference held in Glasgow, Scotland, UK.
The widely adopted practice of secondary surgical cytoreduction in women with platinum-sensitive recurrent ovarian cancer is being called into question as a phase III trial shows no improvement in overall survival (OS) with this approach.
Treatment with the selective PARP* 1/2 inhibitor niraparib after a response to first-line platinum-based chemotherapy significantly extends progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer, including those at high risk of relapse, according to the PRIMA** study presented at ESMO 2019.
A maintenance regimen comprising olaparib and bevacizumab led to greater progression-free survival (PFS) in patients newly diagnosed with advanced ovarian cancer, results of the phase III PAOLA-1/ENGOT-ov25* study showed.
Women with platinum-sensitive ovarian cancer with germline BRCA mutations who relapsed after previously receiving ≥2 lines of chemotherapy demonstrated better objective response rates (ORRs) and progression-free survival (PFS) following treatment with olaparib than platinum-based chemotherapy, according to results of the SOLO3* trial.
According to the Singapore Cancer Registry, ovarian cancer was the fifth most frequent cancer among women in Singapore and accounted for 5.4 percent of all female cancers diagnosed between 2011 and 2015, with an increasing incidence rate through the last four decades.
Use of aspirin or NSAIDs after the diagnosis of ovarian cancer appears to improve ovarian cancer-specific survival, according to data from the ongoing Nurses’ Health Study (NHS) and Nurses’ Health Study II (NHSII).
Women who undergo assisted reproductive technology (ART) treatment for infertility appear to have an elevated risk of ovarian cancer, but the lack of long-term association suggests that detection bias as well as parity and cause of infertility may play roles and not ovarian stimulating hormones, according to a study from Denmark.
Matching targeted therapy to genetic alterations in the tumour improved response rate and long-term survival in patients with advanced cancer who underwent molecular profiling compared with patients who were unmatched to therapy, highlighting the role of molecular testing in precision medicine, the IMPACT* study shows.
A recent study reports a mean growth rate of proximal aorta of about 0.1 mm/year in hypertensive patients with known aortic dilatation. In addition, those with increased rather than normal aortic z score have slower dilatation over time.
Among patients with nonvalvular atrial fibrillation (AF), treatment with apixaban was associated with a lower rate of ischaemic stroke, systemic embolism, and major bleeding compared with rivaroxaban, according to a large study assessing patients in routine care.